Prof. Dr. Andaç Salman

The Overall Burden of Chronic Spontaneous Urticaria – The Current Landscape

British Journal of Dermatology, 2026

DOI 10.1093/bjd/ljag121 PMID 41913980 1 citation (Europe PMC) Source: OpenAlex

Clinical phenotypes and molecular endotypes of chronic urticaria: Linking clinical expression to underlying immune mechanisms

Asia Pacific Allergy, 2026

DOI 10.5415/apallergy.0000000000000279 PMID 41960557 1 citation (Europe PMC) Open-access full textSource: OpenAlex

Management of chronic urticaria: Current status and future prospect

Journal of the European Academy of Dermatology and Venereology, 2026

DOI 10.1111/jdv.70637 PMID 42712073 1 citation (Europe PMC) Source: OpenAlex

Antihistamines

Akademisyen Kitabevi eBooks, 2026

DOI 10.37609/akya.4051.c4809 Source: OpenAlex

Small Molecules

Akademisyen Kitabevi eBooks, 2026

DOI 10.37609/akya.4051.c4819 Source: OpenAlex

Urticaria

Akademisyen Kitabevi eBooks, 2026

DOI 10.37609/akya.4051.c4796 Source: OpenAlex

Geriatric Dermatologic Therapy

Akademisyen Kitabevi eBooks, 2026

DOI 10.37609/akya.4051 Open-access full textSource: OpenAlex

Pruritus (Pruritus in the Elderly)

Akademisyen Kitabevi eBooks, 2026

DOI 10.37609/akya.4051.c4797 Source: OpenAlex

Topical and Systemic Steroids

Akademisyen Kitabevi eBooks, 2026

DOI 10.37609/akya.4051.c4810 Source: OpenAlex

Atopic Dermatitis and Other Dermatitis (Atopic Dermatitis)

Akademisyen Kitabevi eBooks, 2026

DOI 10.37609/akya.4051.c4792 Source: OpenAlex

Performance of omalizumab in patients with mast cell–mediated angioedema with and without wheals

The Journal of Allergy and Clinical Immunology In Practice, 2026

DOI 10.1016/j.jaip.2026.03.004 PMID 41831782 Source: OpenAlex

Editorial: Clinical and molecular aspects of managing chronic urticaria: identifying endotypes, phenotypes, and factors determining responses and resistance to treatment

Frontiers in Allergy, 2026

DOI 10.3389/falgy.2026.1823731 PMID 42022301 Open-access full textSource: OpenAlex

Biomarkers in atopic dermatitis: Current evidence and unmet needs

Journal of the European Academy of Dermatology and Venereology, 2026

DOI 10.1111/jdv.70491 PMID 42360700 Open-access full textSource: OpenAlex

A Practical Guide for Incorporating Emollients in the Treatment of Mild‐to‐Moderate Atopic Dermatitis

JEADV Clinical Practice, 2026

DOI 10.1002/jvc2.70425 Source: OpenAlex

Impact of Chronic Urticaria on Major Life‐Changing Decisions: Greater Burden in Social, Physical, and Job/Career Domains

JEADV Clinical Practice, 2026

DOI 10.1002/jvc2.70433 Source: OpenAlex

Bruton tyrosine kinase inhibition in dermatology: From mechanistic promise to clinical application

Journal of the European Academy of Dermatology and Venereology, 2026

DOI 10.1111/jdv.70837 PMID 42949422 Source: OpenAlex

Biomarkers in Chronic Spontaneous Urticaria: Are We Ready for its Use in Clinical Practice?

Current Treatment Options in Allergy, 2025

DOI 10.1007/s40521-025-00391-2 Source: OpenAlex

Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long‐Term Multicentre Real‐World Study

Clinical & Experimental Allergy, 2025

DOI 10.1111/cea.70067 PMID 40325793 9 citations (Europe PMC) Open-access full textSource: OpenAlex

Clinical Evaluation and Outcome Measures of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria

The Journal of Allergy and Clinical Immunology In Practice, 2025

DOI 10.1016/j.jaip.2025.07.008 PMID 40680928 1 citation (Europe PMC) Source: OpenAlex

Listening to Urticaria Patients Through Social Media: Analyzing the Impact of the COVID-19 Pandemic

Asthma Allergy Immunology, 2025

DOI 10.21911/aai.2025.692 Source: OpenAlex

Filaggrin Gene Variants Among Patients With Atopic Dermatitis in Turkey: A Multicenter Study Investigating Its Relationship With Disease Severity and Clinical/Laboratory Findings

Dermatitis, 2025

DOI 10.1089/derm.2024.0403 PMID 39772616 Source: OpenAlex

Assessing Quality of Life and Family Impact in Adult Atopic Dermatitis Patients Compared to Chronic Spontaneous Urticaria and Psoriasis: A Comparative Cross-Sectional Study

Indian Journal of Dermatology, 2025

DOI 10.4103/ijd.ijd_185_24 PMID 42109546 Open-access full textSource: OpenAlex

Tenoxicam-induced Fixed Drug Eruption Confirmed by Patch Testing

Asthma Allergy Immunology, 2025

DOI 10.21911/aai.2025.729 Source: OpenAlex

Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review

European Journal of Dermatology, 2024

DOI 10.1684/ejd.2024.4600 PMID 38557452 14 citations (Europe PMC) Source: OpenAlex

Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation

JAMA Dermatology, 2024

DOI 10.1001/jamadermatol.2024.2056 PMID 39018068 26 citations (Europe PMC) Open-access full textSource: OpenAlex

Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real‐world data from a large multi‐national UCARE study

Allergy, 2024

DOI 10.1111/all.16334 PMID 39377745 12 citations (Europe PMC) Open-access full textSource: OpenAlex

Psychological Stress and Urticaria: Pathophysiologic and Therapeutic Updates

Current Treatment Options in Allergy, 2024

DOI 10.1007/s40521-024-00375-8 Source: OpenAlex

Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria

Archives of Dermatological Research, 2024

DOI 10.1007/s00403-024-02966-6 PMID 38795119 10 citations (Europe PMC) Open-access full textSource: OpenAlex

Emerging Systemic Treatment Options in Atopic Dermatitis

Balkan Medical Journal, 2024

DOI 10.4274/balkanmedj.galenos.2024.2024-5-78 PMID 38966900 3 citations (Europe PMC) Open-access full textSource: OpenAlex

UCOMB-real life data: treatment strategies for chronic urticaria patients with comorbidities

Journal of Dermatological Treatment, 2024

DOI 10.1080/09546634.2024.2329784 PMID 38508226 2 citations (Europe PMC) Open-access full textSource: OpenAlex

A review of comorbidities in atopic dermatitis

Indian Journal of Skin Allergy, 2024

DOI 10.25259/ijsa_37_2024 Source: OpenAlex

Biological drugs for the treatment of children with chronic spontaneous urticaria

Expert Review of Clinical Immunology, 2024

DOI 10.1080/1744666x.2024.2388689 PMID 39555837 2 citations (Europe PMC) Source: OpenAlex

Urticaria Beyond Omalizumab: What is Next?

Current Treatment Options in Allergy, 2024

DOI 10.1007/s40521-024-00372-x Source: OpenAlex

CONTACT DERMATITIS

Turkiye Klinikleri eBooks, 2024

DOI 10.5336/978-625-395-618-9_p111 Source: OpenAlex

Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study

Journal of Allergy and Clinical Immunology, 2023

DOI 10.1016/j.jaci.2023.07.019 PMID 37574079 15 citations (Europe PMC) Source: OpenAlex

Acute and Chronic Urticaria Diagnosis and Management Taking into Account Their Differences

Current Treatment Options in Allergy, 2023

DOI 10.1007/s40521-023-00333-w Source: OpenAlex

Dermatolojik Hastalıklara Algoritmik Yaklaşım ve Tanısal İpuçları

Akademisyen Kitabevi eBooks, 2022

DOI 10.37609/akya.1231 Open-access full textSource: OpenAlex

Atopic dermatitis diagnosis and treatment consensus report

TURKDERM, 2022

DOI 10.4274/turkderm.galenos.2022.73368 Source: OpenAlex

Symmetrical drug-related intertriginous and flexural exanthema-like eruption: An addition to the spectrum of coronavirus disease 2019-related cutaneous findings

Indian Journal of Dermatology Venereology and Leprology, 2022

DOI 10.25259/ijdvl_165_2022 PMID 36332096 1 citation (Europe PMC) Open-access full textSource: OpenAlex

Management of Natural Rubber Glove Sensitivity

CRC Press eBooks, 2022

DOI 10.1201/9781003126874-19 Source: OpenAlex

Allergic Responses to Powdered Natural Rubber Latex Gloves in Healthcare Workers

CRC Press eBooks, 2022

DOI 10.1201/9781003126874-20 Source: OpenAlex

Public interest in dermatologic symptoms, conditions, treatments, and procedures during the COVID‐19 pandemic: Insights from Google Trends

Dermatologic Therapy, 2021

DOI 10.1111/dth.14895 PMID 33595849 14 citations (Europe PMC) Open-access full textSource: OpenAlex

Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: Real‐life data

Australasian Journal of Dermatology, 2021

DOI 10.1111/ajd.13656 PMID 34156714 11 citations (Europe PMC) Source: OpenAlex

Real‐life effectiveness and safety of dupilumab in adult patients with moderate‐to‐severe atopic dermatitis

Dermatologic Therapy, 2021

DOI 10.1111/dth.15192 PMID 34743366 5 citations (Europe PMC) Open-access full textSource: OpenAlex

Effectiveness of Omalizumab in Patients with Chronic Inducible Urticaria: real‐life experience from two UCARE centres

Journal of the European Academy of Dermatology and Venereology, 2021

DOI 10.1111/jdv.17385 PMID 34013560 8 citations (Europe PMC) Source: OpenAlex

A case series and literature review of erythema palmare hereditarium (Lane’s disease)

Indian Journal of Dermatology Venereology and Leprology, 2021

DOI 10.25259/ijdvl_112_20 PMID 33580943 2 citations (Europe PMC) Open-access full textSource: OpenAlex

Omalizumab Treatment in Chronic Spontaneous Urticaria During Pregnancy: Report of A Case and Review of the Literature

Asthma Allergy Immunology, 2021

DOI 10.21911/aai.599 Source: OpenAlex

The global impact of the COVID‐19 pandemic on the management and course of chronic urticaria

Allergy, 2020

DOI 10.1111/all.14687 PMID 33284457 60 citations (Europe PMC) Open-access full textSource: OpenAlex

Netherton syndrome: Temporary response to dupilumab

Pediatric Dermatology, 2020

DOI 10.1111/pde.14362 PMID 32951242 22 citations (Europe PMC) Source: OpenAlex

Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress

Drugs, 2020

DOI 10.1007/s40265-020-01387-9 PMID 32857360 17 citations (Europe PMC) Source: OpenAlex